Zhejiang Scientific Research Team Achieves New Results in Tumor Treatment

By yqqlm yqqlm

China News Service, Hangzhou, May 7 (Huang Lingyi and Liu Yanpeng) The latest global cancer burden data released by the International Agency for Research on Cancer (IARC) of the World Health Organization in 2020 shows that there will be 19.29 million new cancer cases worldwide in 2020. Among them, China has 4.57 million new cancer cases and 3 million cancer deaths. The number of new cancers and cancer deaths rank first in the world.

How to treat tumors efficiently has attracted more and more attention from the society. On the 7th, the reporter learned from Zhejiang University Hangzhou International Science and Technology Center that the center’s Shen Youqing team has made new progress in tumor nano-drug delivery vehicles and tumor immunotherapy. The relevant results have been published in “Natural Biomedical Engineering” ( Nature Biomedical Engineering and Nature Communications.

External force: “Drumming and spreading style” to break the tumor “defense line”

Introduced by Shen Youqing’s team, solid tumors are like a “sphere” wrapped in layers of cells, which are traditionally Carrier restriction, when the drug reaches the vicinity of the “sphere”, it will stop the “footstep”, it is difficult to break through the layers of cells to penetrate into the tumor.

This time, the team has developed a polymer-drug conjugate with cell membrane affinity, which can bind to tumor cells without adhesion to proteins. The new nano-drug delivery vehicle will effectively solve the above-mentioned problems.

“The carrier non-stick protein is a prerequisite for drugs to enter tumor cells from blood vessels.” The team of researchers explained that the surface of tumor cells is negatively charged, so conventional drug carriers are often positively charged. To facilitate entry into the cell. But the positively charged drug carrier will interact with the protein in the blood, causing its ability to penetrate into the cell weakened.

“The nanomedicine we developed is a polymer (English name OPDEA) that binds to phospholipids. It is not sticky to proteins and can attack and break the line of defense layer by layer.” The team’s scientific researchers said that after intravenous injection, the drug can circulate in the blood, and then maintain a dynamic balance between the plasma and the surface of red blood cells, and ultimately achieve the efficient delivery of cancer drugs, greatly improving the efficacy.

It is reported that this scientific research result not only has great clinical translational value, but will also help design transformational anti-cancer nano-drugs.

Zhejiang Scientific Research Team Achieves New Results in Tumor Treatment


p >Schematic diagram of IOX1 enhanced chemical-immunotherapy mechanism. Photo courtesy of Shen Youqing’s team

Internal power: “self-modification” inhibits tumor growth

If a new type of drug carrier assists tumor treatment through external forces, then immunotherapy is through the treatment of the human body. The transformation of one’s own cells can then accurately deal with tumor cells, thereby enhancing the efficacy.

According to reports, the use of antibodies to block the interaction between receptors and ligands can restore human T cells to normal, thereby helping tumor treatment. However, due to reasons such as poor tumor penetration, large-size antibodies are often difficult to function.

Recently, Shen Youqing’s team discovered a highly effective immunotherapy small molecule-5-carboxy-8-hydroxyquinoline (IOX1), which is combined with the tumor chemotherapy drug doxorubicin (DOX) , Can reduce the growth of solid tumors.

“At present, we have verified through mouse models that this method can eliminate various cancers in mice and make them produce long-term immune memory. IOX1 passes through the JMJD1A/β-catenin/P-gp pathway Inhibit the p-glycoprotein of cancer cells and significantly increase DOX-induced immunostimulatory immunogenic cell death.” The team said that this method opens up new ideas for highly effective antibody-free chemotherapy immunotherapy. (End)